Heron Therapeutics (NASDAQ:HRTX) Earns Overweight Rating from Analysts at Capital One Financial

Equities researchers at Capital One Financial began coverage on shares of Heron Therapeutics (NASDAQ:HRTX - Get Free Report) in a report issued on Tuesday, Marketbeat Ratings reports. The firm set an "overweight" rating and a $6.00 price target on the biotechnology company's stock. Capital One Financial's target price indicates a potential upside of 114.29% from the stock's previous close.

HRTX has been the topic of a number of other reports. Needham & Company LLC restated a "buy" rating and issued a $5.00 price target on shares of Heron Therapeutics in a research report on Thursday, April 11th. StockNews.com upgraded shares of Heron Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, January 16th.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX traded up $0.21 on Tuesday, hitting $2.80. 6,562,568 shares of the company were exchanged, compared to its average volume of 2,806,254. The company's 50 day moving average price is $2.76 and its two-hundred day moving average price is $1.95. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.22. The firm has a market capitalization of $420.92 million, a price-to-earnings ratio of -3.26 and a beta of 1.68.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.08. The company had revenue of $34.23 million for the quarter, compared to the consensus estimate of $30.98 million. Research analysts predict that Heron Therapeutics will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Heron Therapeutics

A number of large investors have recently modified their holdings of HRTX. Victory Capital Management Inc. lifted its holdings in Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company's stock valued at $34,000 after buying an additional 4,617 shares during the period. Commonwealth Equity Services LLC increased its position in shares of Heron Therapeutics by 5.5% during the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company's stock worth $324,000 after acquiring an additional 16,467 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Heron Therapeutics by 61.2% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 48,309 shares of the biotechnology company's stock worth $82,000 after acquiring an additional 18,333 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Heron Therapeutics by 5.8% during the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company's stock worth $364,000 after acquiring an additional 19,345 shares in the last quarter. Finally, ACT Advisors LLC. acquired a new position in Heron Therapeutics during the fourth quarter worth $38,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.